Mylan agreed to pay $30 million to settle a lawsuit claiming it failed to disclose to investors a 2017 U.S. Justice Department probe into whether it overcharged Medicaid for its EpiPen allergy treatment.

Seven drugs approved by the FDA since Aug. 19:

The FDA approved the first treatment for children with rare vasculitis diseases that cause inflammation of blood vessels and reduce blood flow to organs.

St. Mary's Medical Center started a program called "meds-to-beds" several years ago to give patients better access to prescriptions, according to The Intelligencer.

Drugmaker Novo Nordisk's newly approved oral diabetes treatment will cost $772 per month, according to Investor's Business Daily.

Discount retail and pharmacy chain Fred's reached deals with Walgreens Boots Alliance and ExpressRx to sell some of its pharmacy assets, according to The Wall Street Journal.

The FDA expanded approval of a hepatitis C drug that shortens treatment time to eight weeks.

Health systems' pharmaceutical spending is expected to rise by up to 6 percent in 2019, according to a study published in the American Journal of Health-System Pharmacy. For these organizations — which already devote a large portion of their budgets…

The FDA sent a warning letter to a small Atlanta-based drugmaker for sending an email to physicians with information about a pill that appeared to intentionally omit that it was a controlled substance.

GlaxoSmithKline, a British drugmaker, is investing $120 million to expand its manufacturing facility in Upper Merion, Pa., according to BioPharma-Reporter.com.